Aqumeldi (enalapril maleate)
- Region
- 🇪🇺 EU
- Active substance
- enalapril maleate
- Company
- Proveca Pharma Limited
- Status
- Authorised
- Therapeutic area
- Heart Failure
- CHMP opinion
- Thu 14 Sep 2023
- EU approval
- Wed 15 Nov 2023
- Application
- EMEA/H/C/005731
- ATC
- C09AA02
- Official record
- www.ema.europa.eu
Indication
Treatment of heart failure.
Regulatory milestones
No milestones recorded in the last year.
Follow Aqumeldi
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.